

Soeren Mattke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415501/publications.pdf>

Version: 2024-02-01

71
papers

4,468
citations

361045

20
h-index

114278

63
g-index

74
all docs

74
docs citations

74
times ranked

4812
citing authors

#	ARTICLE	IF	CITATIONS
1	Nurse-Staffing Levels and the Quality of Care in Hospitals. <i>New England Journal of Medicine</i> , 2002, 346, 1715-1722.	13.9	1,879
2	Systematic Review: The Evidence That Publishing Patient Care Performance Data Improves Quality of Care. <i>Annals of Internal Medicine</i> , 2008, 148, 111.	2.0	726
3	Utilization of Anesthesia Services During Outpatient Endoscopies and Colonoscopies and Associated Spending in 2003-2009. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1178.	3.8	174
4	Anaplastic Large Cell Lymphoma and Breast Implants: A Systematic Review. <i>Plastic and Reconstructive Surgery</i> , 2011, 127, 2141-2150.	0.7	167
5	A review of methods to measure health-related productivity loss. <i>American Journal of Managed Care</i> , 2007, 13, 211-7.	0.8	166
6	Evidence for the effect of disease management: is \$1 billion a year a good investment?. <i>American Journal of Managed Care</i> , 2007, 13, 670-6.	0.8	127
7	Rigorous Development does not Ensure that Guidelines are Acceptable to a Panel of Knowledgeable Providers. <i>Journal of General Internal Medicine</i> , 2008, 23, 37-44.	1.3	98
8	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 713-720.	0.7	91
9	Untangling Practice Redesign from Disease Management: How Do We Best Care for the Chronically Ill?. <i>Annual Review of Public Health</i> , 2009, 30, 385-408.	7.6	89
10	Anaplastic Large Cell Lymphoma and Breast Implants. <i>Plastic and Reconstructive Surgery</i> , 2011, 128, 629-639.	0.7	89
11	Systematic review of the impact of worksite wellness programs. <i>American Journal of Managed Care</i> , 2012, 18, e68-81.	0.8	84
12	Chronic Stroke Outcome Measures for Motor Function Intervention Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S163-9.	0.9	81
13	The curse of wealth – Middle Eastern countries need to address the rapidly rising burden of diabetes. <i>International Journal of Health Policy and Management</i> , 2014, 2, 109-114.	0.5	69
14	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2015, 3, e296.	0.3	57
15	Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment. , 2017, , .		51
16	Application of patient safety indicators internationally: a pilot study among seven countries. <i>International Journal for Quality in Health Care</i> , 2009, 21, 272-278.	0.9	43
17	The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 421-426.	4.0	30
18	Development of a Model to Predict Healing of Chronic Wounds Within 12 Weeks. <i>Advances in Wound Care</i> , 2020, 9, 516-524.	2.6	29

#	ARTICLE	IF	CITATIONS
19	Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12081.	1.2	28
20	Measuring Hospital Quality: Can Medicare Data Substitute for All-Payer Data?. <i>Health Services Research</i> , 2003, 38, 1487-1508.	1.0	24
21	Who Gets Disease Management?. <i>Journal of General Internal Medicine</i> , 2009, 24, 649-655.	1.3	22
22	Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States. <i>Alzheimer's and Dementia</i> , 2022, 18, 1071-1074.	0.4	21
23	Nurse Staffing and Quality of Care in Hospitals in the United States. <i>Policy, Politics, and Nursing Practice</i> , 2002, 3, 306-308.	0.8	18
24	Understanding the Relationship between Incentive Design and Participation in U.S. Workplace Wellness Programs. <i>American Journal of Health Promotion</i> , 2016, 30, 198-203.	0.9	17
25	Effect of an Employer-Sponsored Health and Wellness Program on Medical Cost and Utilization. <i>Population Health Management</i> , 2013, 16, 1-6.	0.8	16
26	The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey. <i>Journal of the American Board of Family Medicine</i> , 2019, 32, 931-940.	0.8	16
27	Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. <i>Rand Health Quarterly</i> , 2019, 8, 2.	0.6	16
28	Improving Antipsychotic Adherence Among Patients With Schizophrenia: Savings for States. <i>Psychiatric Services</i> , 2015, 66, 343-345.	1.1	15
29	Effect of Disease Management on Prescription Drug Treatment: What Is The Right Quality Measure?. <i>Disease Management: DM</i> , 2007, 10, 91-100.	1.0	14
30	Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States. <i>Alzheimer's and Dementia</i> , 2022, 18, 142-151.	0.4	14
31	Incentives, Program Configuration, and Employee Uptake of Workplace Wellness Programs. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, 30-34.	0.9	13
32	Impact of 2 employer-sponsored population health management programs on medical care cost and utilization. <i>American Journal of Managed Care</i> , 2009, 15, 113-20.	0.8	13
33	Upcoding and Anesthesia Risk in Outpatient Gastrointestinal Endoscopy Procedures. <i>JAMA Internal Medicine</i> , 2016, 176, 855.	2.6	12
34	Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 533-545.	1.0	11
35	Association between state stay-at-home orders and risk reduction behaviors and mental distress amid the COVID-19 pandemic. <i>Preventive Medicine</i> , 2020, 141, 106299.	1.6	11
36	Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer's Treatment. , 2019, , .		11

#	ARTICLE	IF	CITATIONS
37	Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia. <i>Psychiatric Services</i> , 2018, 69, 12-14.	1.1	10
38	Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. <i>Microbial Biotechnology</i> , 2019, 13, 1357-1365.	0.9	10
39	Adoption and use of stand-alone electronic prescribing in a health plan-sponsored initiative. <i>American Journal of Managed Care</i> , 2010, 16, 182-9.	0.8	10
40	Quality Measures Based on Presenting Signs and Symptoms of Patients. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 520.	3.8	8
41	Estimating minimal clinically important differences for two scales in patients with chronic traumatic brain injury. <i>Current Medical Research and Opinion</i> , 2020, 36, 1999-2007.	0.9	7
42	Medicare Coverage of Anesthesia Services During Screening Colonoscopies for Patients at Low Risk of Sedation-Related Complications. <i>JAMA Internal Medicine</i> , 2015, 175, 1848.	2.6	6
43	Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12159.	1.2	6
44	Outpatient Wound Clinics During COVID-19 Maintained Quality but Served Fewer Patients. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 660-665.e5.	1.2	5
45	Anesthesia Service Use and the Uptake of Screening Colonoscopies. <i>Medical Care</i> , 2017, 55, 623-628.	1.1	4
46	Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 752-757.	0.3	4
47	Temporal Trends in Mortality after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis. <i>Structural Heart</i> , 2020, 4, 16-23.	0.2	4
48	The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 669-677.	1.0	4
49	Determining minimally clinically important differences for outcome measures in patients with chronic motor deficits secondary to traumatic brain injury. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1051-1058.	1.4	4
50	Financial Incentives: Only One Piece of the Workplace Wellness Puzzle Comment on "Corporate Wellness Programs: Implementation Challenges in the Modern American Workplace". <i>International Journal of Health Policy and Management</i> , 2013, 1, 311-312.	0.5	4
51	Does Targeting Higher Health Risk Employees or Increasing Intervention Intensity Yield Savings in a Workplace Wellness Program?. <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, 1257-1261.	0.9	3
52	Comment on "Do Workplace Health Promotion (Wellness) Programs Work?". <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, e9.	0.9	3
53	Impact of Event Severity on Hospital Rankings Based on Heart Failure Readmission Rates. <i>Population Health Management</i> , 2019, 22, 243-247.	0.8	3
54	Is Korea Prepared for an Alzheimer's Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests. <i>Annals of Geriatric Medicine and Research</i> , 2021, 25, 33-38.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Memory care approaches to better leverage capacity of dementia specialists: a narrative synthesis. <i>Neurodegenerative Disease Management</i> , 2021, 11, 239-250.	1.2	3
56	How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy. <i>Current Alzheimer Research</i> , 2021, 17, 819-822.	0.7	3
57	Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs. <i>Alzheimer's and Dementia</i> , 2022, 18, 7-9.	0.4	3
58	Association of wound healing with quality and continuity of care and sociodemographic characteristics. <i>American Journal of Managed Care</i> , 2022, 28, e146-e152.	0.8	3
59	Testing the DMAA's Recommendations for Disease Management Program Evaluation. <i>Population Health Management</i> , 2008, 11, 241-245.	0.8	2
60	Detection of Undiagnosed Disease in Medicare Beneficiaries After a Clinical Home Visit. <i>Population Health Management</i> , 2017, 20, 41-47.	0.8	2
61	Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 835-842.	0.3	2
62	Voluntary partial capitation: the Community Nursing Organization Medicare demonstration. <i>Health Care Financing Review</i> , 2005, 26, 21-37.	1.8	2
63	Why would Canada have the longest wait times for an Alzheimer's treatment among the G7 countries? A policy analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
64	Sterilization of Endoscopic Instruments. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 524.	3.8	1
65	From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?. , 2022, , 343-353.		1
66	Comment on Steinberg et al. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, e114.	0.9	0
67	TWO-YEAR RESULTS AFTER IMPLANTATION OF AN ULTRATHIN, BIORESORBABLE POLYMER SIROLIMUS-ELUTING CORONARY STENT COMPARED TO A THIN, DURABLE POLYMER EVEROLIMUS-ELUTING STENT: HEALTH ECONOMIC EVALUATION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1152.	1.2	0
68	Impact of blood biomarkers on cost and wait time in diagnosing treatment-eligible patients for Alzheimer's disease: A simulation study. <i>Alzheimer's and Dementia</i> , 2020, 16, e037200.	0.4	0
69	How prepared are the EU's countries' health systems to deliver a disease-modifying treatment for Alzheimer's?. <i>Alzheimer's and Dementia</i> , 2020, 16, e037257.	0.4	0
70	Results from a national survey on chronic care management by health plans. <i>American Journal of Managed Care</i> , 2015, 21, 370-6.	0.8	0
71	Projection of net savings to U.S. state Medicaid programs from reduced nursing home utilization due to an Alzheimer's treatment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0